Skip to main content
GBLX logo

GB Sciences, Inc. (GBLX) Stock Price & Analysis

GB Sciences, Inc. (GBLX) — price $0.0001 (-50.00%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0001 −$0.0001 (-50.00%)

GB Sciences, Inc. · GBLX

GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines. They target conditions like Parkinson's disease and chronic pain with cannabinoid-inspired therapies.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RLYB · Rallybio Corporation · 82 /100
  • ICCC · ImmuCell Corporation · 82 /100
  • ORMP · Oramed Pharmaceuticals Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0001
Change on the day-50.00%
52-week range$0.0001 – $0.5001
Shares traded on the day31.0K

Price & events

Other perspectives

Council score for GB Sciences (GBLX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is GB Sciences (GBLX), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. GB Sciences, Inc. (GBLX) is the company analyzed here. It employs 2 people and is led by Andrea Small-Howard. In Q3 FY2024 it reported revenue of $97,235 and net income of -$100,355.

2 · Latest results

What do the latest results show for GB Sciences (GBLX)?

Short answer · as of

The most recent reported quarter, Q3 FY2024, carried revenue of $97,235.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2024$97,235-$100,355-$0.0002 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for GB Sciences (GBLX)?

Short answer · as of

The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 28.0% · current ratio 0.02.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
2
Purchases
7
Sales
5
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GBLX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GBLX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

GB Sciences Stock: Key Questions Answered

These answers are editorial: 1 of these 1 answer is drawn from the GBLX research dossier (written Mar 17, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What are the main risks for GBLX?

The main risks for GB Sciences, Inc. include its limited financial resources, dependence on external funding, and the inherent uncertainties of drug development. The company's pre-clinical programs face the risk of failure in clinical trials or regulatory rejection.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.